AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$SOPH

Van Well Daan sold $50K of SOPH

Van Well Daan (Chief Legal Officer) sold 6,168 shares of SOPHiA GENETICS SA (SOPH) at $8.12 on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Van Well Daan
Published Oct 7, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SOPH
Bearish
medium confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHBearishLow
01

Why it matters

The sale is small and unlikely to move the stock significantly, but it adds to the flow of insider activity data.

02

Market read

Provides a routine insider sale update with limited trading relevance.

03

Timing

after filing on Oct 7, 2026

Relevance 2/10Novelty 2/10Timing: after filing on Oct 7, 2026

Background

SEC Form 4 filing discloses an insider transaction by SOPHiA GENETICS' Chief Legal Officer.

Company-level read

Ticker impact

$SOPHBearishMedium confidence
Context

Chief Legal Officer Van Well Daan sold 6,168 shares for $50,100 via a 10b5‑1 plan on Oct 5, 2026.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

A $50k sale by a senior officer is small relative to total holdings, but signals potential insider sentiment.

Key entities

  • company
    SOPHiA GENETICS SA

    Swiss biotech company listed on NASDAQ under SOPH.

  • person
    Van Well Daan

    Chief Legal Officer of SOPHiA GENETICS.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SOPH insider trading history →

Related articles

AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min
AUG 4
$SOPHHighAI 9/10

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

prnewswire.com6 min
AUG 4
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q2 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30,

SEC EDGAR 6-K2 min
AUG 4
$SOPHMed

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

finanznachrichten.de4 min